Biomarkers of immunotherapy in non-small cell lung cancer

Immunotherapy has markedly improved the survival rate of patients with non-small cell lung cancer (NSCLC) and has introduced a new era in lung cancer treatment. However, not all patients with lung cancer benefit from checkpoint blockade, and some suffer from notable immunotoxicities. Thus, it is cru...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lingling, Hu, Yue, Wang, Shengchao, Shen, Jiali, Wang, Xiaochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471728/
https://www.ncbi.nlm.nih.gov/pubmed/32934707
http://dx.doi.org/10.3892/ol.2020.11999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471728/
https://www.ncbi.nlm.nih.gov/pubmed/32934707
http://dx.doi.org/10.3892/ol.2020.11999

Ejemplares similares